Andrews Timothy K. 4

Accession 0001562180-19-004219

CIK 0001656328other

View on SEC.gov Company Profile

Filed

Aug 7, 8:00 PM ET

Accepted

Aug 8, 4:44 PM ET

Size

31.9 KB

Accession

0001562180-19-004219

Insider Transaction Report

Form 4

Period: 2019-08-06

Sienna Biopharmaceuticals, Inc.SNNA

Andrews Timothy K.

General Counsel & Secretary

Transactions

Award
Common Stock
2019-08-06+50,000→ 145,558 total
Disposition to Issuer
Stock Options (Right to buy)
2019-08-06−8,518→ 0 total
Exercise: $15.00Exp: 2027-07-26→ Common Stock (8,518 underlying)
Disposition to Issuer
Stock Options (Right to buy)
2019-08-06−22,500→ 0 total
Exercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying)
Award
Stock Options (Right to buy)
2019-08-06+22,500→ 22,500 total
Exercise: $0.71Exp: 2029-01-01→ Common Stock (22,500 underlying)
Disposition to Issuer
Stock Options (Right to buy)
2019-08-06−60,000→ 0 total
Exercise: $15.08Exp: 2028-06-01→ Common Stock (60,000 underlying)
Disposition to Issuer
Stock Options (Right to buy)
2019-08-06−18,290→ 0 total
Exercise: $2.32From: 2019-01-01Exp: 2029-01-01→ Common Stock (18,290 underlying)
Award
Stock Options (Right to buy)
2019-08-06+8,518→ 8,518 total
Exercise: $0.71Exp: 2027-07-26→ Common Stock (8,518 underlying)
Award
Stock Options (Right to buy)
2019-08-06+22,500→ 22,500 total
Exercise: $0.71Exp: 2029-01-01→ Common Stock (22,500 underlying)
Disposition to Issuer
Stock Options (Right to buy)
2019-08-06−22,500→ 0 total
Exercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying)
Award
Stock Options (Right to buy)
2019-08-06+60,000→ 60,000 total
Exercise: $0.71Exp: 2028-06-01→ Common Stock (60,000 underlying)
Award
Stock Options (Right to buy)
2019-08-06+18,290→ 18,290 total
Exercise: $0.71From: 2019-01-01Exp: 2029-01-01→ Common Stock (18,290 underlying)

Holdings

Common Stock
(indirect: See Footnote)
15,000
Common Stock
(indirect: See Footnote)
10,000

Footnotes (9)

[F1]Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
[F2]Includes a total of 2,916 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
[F3]The shares are held by Steelhead Bioventures LLC, a limited liability company in which the Reporting Person holds a controlling interest.
[F4]The shares are held directly by the Andrews Living Trust (the "Trust"), of which the Reporting Person serves as co-trustee. The Reporting Person and members of his immediate family are beneficiaries of the Trust. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock held by the Trust except to the extent of his pecuniary interest therein.
[F5]The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
[F6]Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
[F7]Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
[F8]Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
[F9]Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Sienna Biopharmaceuticals, Inc.

CIK 0001656328

→

Entity typeother

Related Parties

filerCIK 0001711464

Filing Metadata

Form type: 4
Filed: Aug 7, 8:00 PM ET
Accepted: Aug 8, 4:44 PM ET
Size: 31.9 KB

View on SEC.gov